Biocad joins ranks working on mRNA vaccine against coronavirus

19 March 2020

Russian biotech company Biocad says it has started research in order to create an mRNA vaccine against SARS-COV-2 (coronavirus).

Development will be based on previous pipelines for mRNA-oncovaccines creation, an area where the company has a great expertise. The first animal studies are scheduled for the end of April.

According to Biocad chief executive Dmitry Morozov, today the whole world is working on the search for coronavirus treatment, adding: “By now, 66 companies around the world have announced the development of drugs against SARS-COV-19, 51 of them are working on vaccines, 15 on DNA, RNA or small molecules based drugs. In my opinion, the more intellectual forces are involved in solving the problem, the sooner the world can get over this challenge".

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK